Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LARIAM vs ARAKODA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mefloquine is a 4-quinolinemethanol antimalarial agent that acts as a blood schizontocide. Its exact mechanism is unknown, but it is thought to inhibit heme polymerase, leading to toxic accumulation of free heme in the parasite.
ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.
Treatment of mild to moderate acute malaria caused by Plasmodium falciparum (including chloroquine-resistant strains) or Plasmodium vivax,Prophylaxis of malaria in travelers to areas with chloroquine-resistant P. falciparum,Off-label: treatment of chloroquine-sensitive malaria when other agents are not available
Radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection
For malaria prophylaxis: 250 mg (base) orally once weekly starting 1-2 weeks before travel, continuing weekly during stay and for 4 weeks after leaving endemic area. For malaria treatment: 1250 mg (base) orally as a single dose, divided if needed (750 mg followed by 500 mg after 6-12 hours). Route: oral. Frequency: weekly for prophylaxis; single dose for treatment.
400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).
Terminal elimination half-life: approximately 3 weeks (range 13–33 days); prolonged due to extensive tissue distribution and slow release from erythrocytes.
Terminal elimination half-life: approximately 14-16 days (range 12-19 days) in healthy adults; this long half-life is due to extensive tissue distribution and slow release from tissues, providing prophylactic coverage for up to 4 weeks after a single dose.
Primarily metabolized by cytochrome P450 (CYP) 3A4 to inactive metabolites. It also undergoes enterohepatic recirculation.
Primarily metabolized by CYP2D6 and monoamine oxidase (MAO). Tafenoquine undergoes extensive metabolism including N-dealkylation and oxidation.
Hepatic metabolism (primarily CYP3A4) followed by biliary/fecal elimination; ~40% unchanged in feces, ~9% as metabolites in urine, minimal renal excretion of parent drug (<5%).
Biliary/fecal: ~90% unchanged; renal: <1% unchanged (dose-proportional urinary excretion of tafenoquine is minimal, with most eliminated via feces as unchanged drug and minor metabolites).
Approximately 98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
~99.5% bound to human serum albumin (HSA); binding is high and saturable, with unbound fraction slightly increasing at high concentrations.
Vd: 15–30 L/kg; extensive distribution into tissues, including erythrocytes (high concentration), liver, lungs, and spleen.
Apparent Vd: ~2000 L (or ~24-30 L/kg based on 70 kg), indicating extensive tissue distribution (concentrated in red blood cells, liver, lungs, and adipose tissue).
Oral: ~85% (well absorbed); not available parenterally in the US.
Oral: ~100% (absolute bioavailability not formally determined, but absorption is complete with minimal first-pass metabolism; relative bioavailability is high based on AUC and clinical efficacy).
No specific dosing adjustment required for renal impairment, but caution in GFR <30 m L/min due to limited data; monitor for adverse effects.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
Contraindicated in patients with significant hepatic impairment (Child-Pugh class B or C). For mild impairment (Child-Pugh class A), no adjustment needed but use with caution.
Contraindicated in Child-Pugh Class B or C. Use with caution in mild hepatic impairment (Child-Pugh Class A) with no dose adjustment.
Prophylaxis and treatment: 15-25 mg base/kg orally; maximum 1250 mg. For children weighing ≤45 kg: 5 mg base/kg weekly for prophylaxis; for treatment, same mg/kg as adults. Dosing based on mefloquine base. Not recommended for children <5 kg or <3 months.
Safety and efficacy not established in pediatric patients (<18 years).
No specific dose adjustment, but monitor for neuropsychiatric and cardiac effects (QT prolongation, bradycardia). Use caution due to age-related decline in hepatic and renal function, and potential drug interactions.
No specific dose adjustment; use with monitoring for renal function due to age-related decline and potential for increased adverse effects.
WARNING: Mefloquine can cause serious psychiatric and neurological adverse reactions, including suicide, hallucinations, anxiety, depression, paranoia, confusion, dizziness, and seizures. Use caution in patients with recent history of depression, generalized anxiety disorder, psychosis, or schizophrenia. Discontinue immediately if psychiatric or neurological symptoms occur. Not recommended for prophylaxis in patients with active or recent depression, generalized anxiety disorder, psychosis, or schizophrenia.
ARAKODA can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD testing must be performed before prescribing due to risk of hemolytic anemia.
Psychiatric effects: suicidal ideation, hallucinations, anxiety, depression; Neurologic effects: dizziness, vertigo, seizures; QT prolongation (caution with drugs that prolong QT); use in pregnancy only if benefit outweighs risk; avoid in patients with cardiac conduction disorders; may cause visual disturbances; use caution with activities requiring alertness.
Hemolytic anemia in G6PD-deficient patients (contraindicated in G6PD deficiency without prior testing),Methemoglobinemia (rare, monitor for cyanosis and dyspnea),Psychiatric effects including anxiety, depression, and insomnia,Hepatotoxicity (rare, monitor liver function),Use in pregnancy: not recommended (risk of hemolysis in G6PD-deficient fetus),Lactation: avoid if breastfeeding infant is G6PD deficient
History of hypersensitivity to mefloquine or related compounds (e.g., quinine); active or recent history of depression, generalized anxiety disorder, psychosis, schizophrenia, or other major psychiatric disorders; history of convulsions or epilepsy; concurrent use with halofantrine or other drugs that prolong QT interval.
G6PD deficiency (without confirmed normal G6PD activity),Known hypersensitivity to tafenoquine or any 8-aminoquinoline,Use in children <16 years (safety not established),Severe renal impairment (e GFR <30 m L/min),Lactation in infants with G6PD deficiency or unknown G6PD status
Grapefruit juice may increase mefloquine concentrations and risk of side effects; avoid concurrent use. Take with food or milk to reduce gastrointestinal upset. No other significant food interactions.
Take with a fatty meal to increase absorption. No specific dietary restrictions. Avoid grapefruit juice as it may alter metabolism.
Pregnancy Category C. In animal studies, mefloquine (LARIAM) has been shown to be teratogenic in mice (cleft palate, anophthalmia) and rats (hydrocephalus, anophthalmia) at doses similar to human therapeutic doses. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed. Because malaria infection in pregnancy carries significant maternal and fetal risk, treatment of confirmed malaria with mefloquine is not contraindicated. Prophylaxis should be avoided in pregnancy unless travel to a high-risk area is unavoidable. First trimester: known fetal risks; second and third trimesters: limited data suggest no increased malformations, but caution advised.
FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.
Mefloquine is excreted in human breast milk in small amounts. The milk-to-plasma ratio (M/P) is approximately 0.1-0.2. Studies indicate that the amount ingested by a nursing infant is about 3-4% of the maternal weight-adjusted dose, which is below the therapeutic pediatric dose. The American Academy of Pediatrics considers mefloquine compatible with breastfeeding. Monitor infant for potential adverse effects (e.g., gastrointestinal disturbance, sleep disturbance).
Excreted in human milk; M/P ratio unknown. Potential for adverse effects in infant; use caution, consider discontinuing breastfeeding.
No specific dosing adjustments are routinely recommended for mefloquine in pregnancy based on pharmacokinetic changes. Pregnancy may alter drug disposition, but studies show mefloquine clearance is not significantly changed. Standard adult dosing for prophylaxis (250 mg once weekly) and treatment (1250 mg in divided doses) is generally used. However, due to increased volume of distribution and altered protein binding in pregnancy, some experts consider an increased dose or more frequent monitoring for efficacy, especially in second and third trimesters. Current guidelines (CDC, WHO) do not mandate dose adjustment, but caution is advised in malaria treatment to ensure adequate exposure.
No established dose adjustments; pharmacokinetic changes in pregnancy may require monitoring drug levels and clinical response.
Lariam (mefloquine) is used for malaria prophylaxis and treatment. Neuropsychiatric effects (anxiety, depression, hallucinations) can occur even weeks after discontinuation. Caution in patients with history of seizures or psychiatric disorders. Use with caution in patients with cardiac conduction abnormalities due to potential QT prolongation. Administer with food to reduce gastrointestinal side effects. Not recommended for patients with severe hepatic impairment.
ARAKODA (tafenoquine) is indicated for radical cure of Plasmodium vivax malaria. Assess G6PD status before prescribing; contraindicated in G6PD-deficient patients due to hemolytic anemia risk. Monitor for methemoglobinemia. Avoid use in pregnancy/lactation. Take with food to enhance absorption.
Take exactly as prescribed, usually once weekly for prophylaxis starting 2 weeks before travel and continuing for 4 weeks after leaving area.,Report any symptoms of anxiety, depression, confusion, or unusual dreams immediately.,May cause dizziness or balance problems; avoid driving or operating machinery until reaction is known.,Use effective contraception during treatment and for 3 months after last dose as it may cause fetal harm.,Avoid grapefruit juice as it may increase side effects.
Take with food to improve absorption.,You must be tested for G6PD deficiency before starting this medication.,Report any signs of anemia, dark urine, or yellowing of eyes/skin.,Avoid use during pregnancy or breastfeeding.,Do not drive if you experience dizziness or blurred vision.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LARIAM vs ARAKODA, answered by our medical review team.
LARIAM is a Antimalarial that works by Mefloquine is a 4-quinolinemethanol antimalarial agent that acts as a blood schizontocide. Its exact mechanism is unknown, but it is thought to inhibit heme polymerase, leading to toxic accumulation of free heme in the parasite.. ARAKODA is a Antimalarial that works by ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LARIAM and ARAKODA depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LARIAM is: For malaria prophylaxis: 250 mg (base) orally once weekly starting 1-2 weeks before travel, continuing weekly during stay and for 4 weeks after leaving endemic area. For malaria treatment: 1250 mg (base) orally as a single dose, divided if needed (750 mg followed by 500 mg after 6-12 hours). Route: oral. Frequency: weekly for prophylaxis; single dose for treatment.. The standard adult dose of ARAKODA is: 400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LARIAM and ARAKODA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LARIAM is classified as Category C. Pregnancy Category C. In animal studies, mefloquine (LARIAM) has been shown to be teratogenic in mice (cleft palate, anophthalmia) and rats (hydrocephalus, anophthalmia) at doses s. ARAKODA is classified as Category C. FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.